Kornimate/medical-research-clean huggingface dataset:
minimizing the utilization of voiding cystourethrography for patients with antenatal hydronephrosis

Conditions: Antenatal Hydronephrosis; Post-natal Hydronephrosis

Summary: it has previously been found that there is no correlation between degree of hydronephrosis and presence of reflux; however this is oftentimes the criteria physicians use to obtain a vcug.

investigators conducted a previous retrospective study to evaluate other possible findings on ultrasound that may better predict reflux. investigators found that if a postnatal ultrasound showed any of the three findings of hydroureter, duplication or dysmorphic kidney, then the odds ratio of detecting reflux was 8.07 (95%ci 3.86, 16.87). the purpose of this study is to perform a randomized prospective study to validate this retrospective study. investigators hypothesis is that patients with hydronephrosis alone will be more likely to have negative vcug studies; hence obtaining a vcug for this indication may not be warranted.

Eligibility criteria:
inclusion criteria: * patients with a history of antenatal hydronephrosis who have a post-natal ultrasound demonstrating hydronephrosis alone and no other abnormalities exclusion criteria: * patients with a post-natal ultrasound demonstrating bilateral hydronephrosis * patients with a history of posterior urethral valve or when a valve is suspected * patients who have hydronephrosis on ultrasound as well as other findings including duplication, hydroureter, dysmorphic kidneys, or bladder abnormalities
barbed suture versus traditional suture material for laparoscopic myomectomy

Conditions: Fibroids

Summary: the objective of this study is to determine if the use of a new type of barbed suture material for laparoscopic myomectomy (surgical removal of fibroids) versus the traditional approach of suturing with conventional suture material to close the uterine defect once the fibroid has been removed, improves surgical outcomes. specifically, the investigators will investigate the effect of barbed suture on operative time, blood loss, adverse post-operative events and hospital stay.

although the laparoscopic myomectomy has benefits over the abdominal approach, such as less blood loss, less hemoglobin drop post-operatively, decreased post-operative pain and fewer overall complications, it is a difficult procedure, which often requires greater operative time to perform. in the current climate of attempting to reduce health care expenditures, even though the minimally invasive approach offers the advantage of reduced hospital stay, a deterrent for hospital administration and surgeons may be the increased operative time it may require. barbed suture is a relatively new material available in gynecologic surgery. barbs are cut into the suture with the barbs facing in a direction opposite that of the needle. the barbs allow for anchoring of the suture in tissues, which prevents migration and allows suturing without knot tying. this study will be a single-centre non-blinded randomized controlled trial comparing laparoscopic myomectomy with barbed suture versus traditional suture material.

Eligibility criteria:
inclusion criteria: * women who are planning to undergo laparoscopic myomectomy exclusion criteria: * greater than five fibroids * uterus extending beyond the umbilicus * major medical comorbidity or psychiatric illness, which could affect follow-up and/or compliance * patients undergoing concomitant surgical procedures at the time of myomectomy (such as resection of endometriosis or ovarian cystectomy) * pregnancy (all patients will have serum pregnancy testing prior to surgery) * patients with any suggestion of abnormal pathology on imaging or endometrial biopsy

Keywords: fibroids laparoscopic myomectomy barbed suture
bacterial ecology of pilonidal cysts

Conditions: Pilonidal Cysts

Summary: bacterial ecology of pilonidal cysts single centre retrospective exploratory study of medical data contained in the medical records of patients operated on in the centre between 01/08/2020 and 30/11/2020.

from the medical records of a series of patients treated for pilonidal cysts: 1. describe the bacteriological analyses performed on a series of non-abscessed pilonidal cysts before laser treatment 2. compare the bacterial flora of cysts operated on in the first instance and those reoperated on this is a retrospective monocentric study of medical data contained in the medical records of patients operated on for pilonidal cysts and who received the same protocol: * antibiotic prophylaxis (injection of 2g of augmentin) * treatment of the cyst by laser, under general anaesthesia, after dilatation of the pilonidal sinus, evisceration and bacteriological swabbing. * post-operative monitoring and local care

Eligibility criteria:
inclusion criteria: * patient aged 18 years or older, * patient who has been informed about the research; * patient with a pilonidal cyst treated with holmium laser during a scheduled procedure. exclusion criteria: * patient under legal protection, guardianship or curatorship; * patient who has indicated his opposition to the use of his data; * patient undergoing emergency surgery for an abscess.
efficacy of albumin interferon alfa-2b with ribavirin compared to peg-ifn alfa-2a with ribavirin in ifn naive patients geno2/3

Conditions: Chronic Hepatitis C

Summary: this is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa-2b (alb-ifn)in combination with ribavirin compared with peginterferon alfa-2a (pegasys or peg-ifna2a) in combination with ribavirin in subjects with chronic hepatitis c, genotype 2/3 who are ifna treatment naive.


Eligibility criteria:
key inclusion criteria: * diagnosis of chronic hepatitis c. * liver biopsy performed within 2 years of day 0 or during screening. * infected with hepatitis c virus genotype 2/3. * interferon alfa treatment naïve (ie, have never been treated with an interferon product). * subjects are eligible to enter the study if they (or their partners) are not pregnant or nursing, are sterile, or of non childbearing potential, or are willing to practice abstinence or use appropriate birth control methods during the study and for 7 months after the last dose of ribavirin. * have compensated liver disease. key exclusion criteria: * decompensated liver disease including those subjects with a past history or presence of ascites, bleeding varices or hepatic encephalopathy. * history of moderate, severe or uncontrolled psychiatric disease, especially depression, including a history of hospitalization or prior suicidal attempt. * positive for human immunodeficiency virus (hiv-1) or hepatitis b surface antigen (hbsag). * clinical diagnosis of other causes of chronic liver disease including but not limited to hepatitis b, autoimmune hepatitis, primary biliary cirrhosis, alcoholic liver disease, hemochromatosis, wilson's disease, or alpha 1-antitrypsin deficiency. * a history of immunologically mediated disease (eg, rheumatoid arthritis, inflammatory bowel disease, moderate/severe psoriasis, sarcoidosis, systemic lupus erythematosus). * active seizure disorder within the last 2 years. * organ transplant other than cornea and hair transplant. * clinically significant hemoglobinopathy (eg, thalassemia, sickle cell anemia). * cancer within the last 5 years(with the exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma of the uterine cervix). * drug or alcohol addiction within the last 6 months. subjects in a supervised methadone treatment program may be enrolled in the study. * received any experimental agent within 28 days prior to day 0.

Keywords: chronic hepatitis c hepatitis c chc hepc genotype 1 hepatitis hcv
therapeutical assessment of compression armsleeves for lymphatic indications

Conditions: Lymphedema

Summary: examination of therapeutical effects of different types of armsleeves in treating lymphatic diseases after breast cancer surgery during maintenance phase 1. thesis: - all types should be equal regarding volume reduction 2. thesis: armsleeves manufactured with microfibre yarn are expected to be * better in wearing comfort and * better in handling features.

1. thesis: * measuring of arm volume by "inverse water-volumetry" (see later) * measuring of circumference cd * measuring of circumference cg * photodocumentation in 2 positions(during each round) 2. thesis * questionaire for patients * in the beginning * after 1 week * after 2 weeks (at the end of a wearing period) * questionaire for study nurse (at the end of a wearing period)

Eligibility criteria:
inclusion criteria: * women with a secondary arm-lymphedema for at least 3 months * willingness to wear compression arm-sleeves for at least 12 hours per day * maintenance phase, where no significant further reduction of arm-volume can be achieved * lymphedema in stadium 1 or 2 * age: at least 18 years * signed consent form by the patient * sufficient knowledge in national language exclusion criteria: * edema not completely reduced to "maintenance phase" * immobilized patient * acute deep vein thrombosis in arm * directly after arm-vein-thrombosis * acute arm erysipelas * malignant edema * existent lipedema * arterial occlusion * distinctive neuropathy in upper limbs * neurinoma in upper limbs * chronic pain after plastic surgery in upper limbs, shoulder or breast * change in drug treatment, that can influence edema situation during the study * pregnant women * breast giving mothers * not signed consent form * participation in a second clinical trial

Keywords: secondary arm-lymphedema breast cancer related arm-lymphedema
continuous ambulatory cardiac monitoring for recurrent atrial fibrillation after sepsis

Conditions: Atrial Fibrillation; Sepsis; Infections; Cardiac Arrhythmia

Summary: to detect atrial fibrillation after infection.

this study will prospectively recruit patients who are admitted to cuh general medical wards due to an infection or sepsis and develop new/first diagnosed transient af. in cuh, our previous projects have shown that around 1500 patients are admitted under general medicine each month at least 1 new diagnosis of af is made each day (30/month)26. in particular to the cohort that develop sepsis, they may well be frail and elderly where anticoagulation is often not prescribed as a result 27 unless definitive diagnosis of recurrent af would be made. the cams-af study will closely tie in with an already existing stroke prevention service at cuh (sos-af) who are already screening for patient admitted with af on general medical wards and will therefore be able to identify those with new af during an episode of sepsis. potential participants will be approached by the study investigators prior to discharge and if they are in sinus rhythm written consent will be obtained to place a non-invasive wearable cardiac monitor patch for 14-days, to detect any subclinical arrhythmias, particularly af.

Eligibility criteria:
inclusion criteria: * age \>18 * admission with any infection or sepsis * transient af * under general medicine * can be anticoagulated or not * sinus rhythm at discharge or point of zio patch placement exclusion criteria: * previous history of af or paroxysmal af * age less than 18 years * pregnancy * active and known malignancy * recent cardiac or non-cardiac surgery (3 months) * recent myocardial infarction (3 months) * individuals with skin allergies to plasters and adhesive devices * chest wall deformity, skin condition over sticker site * history of thyroid disease * current alcohol intake above recommended limits * already has a cardiac monitor or pacemaker inserted * known contraindication for anticoagulation therapy * patients who lack capacity or have an estimated life expectancy \< 1 year

Keywords: atrial fibrillation sepsis anticoagulation
intra oral kinetics of fluoride containing dentifrices

Conditions: Tooth Erosion

Summary: the aim of this study is to assess the impact of formulation differences on fluoride retention clearance with us levels of fluoride (1150 ppm of fluoride) by evaluating and comparing between treatments the concentrations of fluoride and calcium ions in saliva over 60 minutes after a single brushing with us marketed fluoridated dentifrices and following a dietary acid challenge post 60 minutes of brushing with study treatment.


Eligibility criteria:
inclusion criteria: * demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form * aged 18-65 years * understands and is willing, able and likely to comply with all study procedures and restrictions * good general and mental health with, in the opinion of the investigator or medically qualified designee: 1. no clinically significant and relevant abnormalities of medical history or oral examination 2. absence of any condition that would impact on the participant's safety or well being or affect the individual's ability to understand and follow study procedures and requirements * a minimum of 20 permanent natural teeth * a gum-base stimulated whole saliva flow rate ≥ 0.8 ml/min and an unstimulated whole saliva flow rate ≥ 0.5 ml/min. exclusion criteria: * pregnant or breast feeding women * presence of chronic debilitating disease. * any condition that causes xerostomia as determined by the investigator. * evidence of untreated caries. * gross periodontal disease. * tongue or lip piercing or presence of dental implants. professional tooth cleaning or dental treatment during study. oral surgery or extraction within 6 weeks of the screening visit. * self reported oral symptoms including lesions, sores or inflammation * known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients * currently taking antibiotics or have taken antibiotics within 2 weeks of the screening visit * any medication that could affect salivary flow or cause xerostomia as determined by the investigator * use of multivitamins, calcium supplements and or fluoride supplements within 7 days of treatment phase * participant unwilling to abstain from smoking for at least 4 hours on the day of each test visit * recent history (within the last year) of alcohol or other substance abuse.
psychosocial treatment for attention deficit hyperactivity disorder (adhd) type i

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: the purpose of this study is to develop and implement a treatment that focuses on behaviors to reduce symptom severity and functional impairment in patients with attention deficit hyperactivity disorder, predominantly inattentive type (adhd-i). the long-term goal of this study is to apply the treatment to larger-scale trials to determine its effectiveness and generalizability.

adhd-i is a highly prevalent and serious childhood disorder that affects academic and social development. the symptoms of adhd-i differ from those of the well-studied adhd combined type. unfortunately, studies of psychosocial interventions for adhd-i are currently unavailable. effective treatments for adhd-i are still needed. participants are randomly assigned to receive either a behavioral intervention or treatment as usual for 10 to 12 weeks. the behavioral intervention includes parent and child skill development groups, family meetings, and consultation with the child's teacher to address attention problems and areas of impairment at home and school. parent and child interviews, teacher and child ratings, and psychoeducational testing are used to assess participants. participants are assessed post-treatment and at a 2-month follow-up visit.

Eligibility criteria:
inclusion criteria: * adhd, predominantly inattentive type * public or private school attendance * english speaking
mostafa maged maneuver in comparison with bimanual uterine compression to control post-partum hemorrhage

Conditions: Post-partum Hemorrhage

Summary: the current study aimed to investigate the effectiveness of the mostafa maged maneuver compared to bimanual uterine compression in controlling postpartum hemorrhage during vaginal delivery. the study subjects were categorized into two groups. the first group was managed by the mostafa maged maneuver , whereas the second group was managed by routine bimanual uterine compression. investigators attempted to determine the duration of each maneuver required until the investigator became exhausted, as well as whether or not oxytocin was administered later in each maneuver .


Eligibility criteria:
inclusion criteria: - female and pregnant exclusion criteria: * hematological diseases morbid obese smoking

Keywords: mostafa maged maneuver bimanual uterine compression vaginal delivery postpartum hemorrhage
an imaging study of 64cu-sartate using positron emission tomography in patients with neuroendocrine tumours

Conditions: Neuroendocrine Tumors

Summary: the primary purpose of this study is to examine the safety and potential effectiveness of a drug molecule called 64cu-sartate as a potential new way to detect neuroendocrine cancers.


Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. age greater than or equal to 18 years 3. life expectancy greater than or equal to 8 weeks 4. low and intermediate grade (ki-67 index \<20%) neuroendocrine tumors (net) 5. at least one site of active somatostatin receptor positive malignancy, as demonstrated on the pre-study 68ga-dotatate pet/ct scan performed as part of routine clinical care 6. subjects with an estimated glomerular filtration rate (egfr) greater than 60ml/min as measured using the mdrd formula (modification of diet in renal disease). 7. eastern cooperative oncology group (ecog) performance score of 0-2 exclusion criteria: 1. pregnant or breastfeeding females 2. known sensitivity or allergy to somatostatin analogues 3. subjects who have received interventional treatment for their net in the interval between 68ga-dotatate pet/ct \& 64cu-sartate pet/ct scan 4. treatment with long acting somatostatin analogues within 28 days prior to the administration of investigational product 5. treatment with short acting somatostatin analogues within 24hrs prior to the administration of investigational product 6. qtc interval greater than 0.44seconds as measured by screening ecg 7. any serious medical condition which the investigator feels may interfere with the procedures or evaluations of the study 8. patients unwilling or unable to comply with protocol or with a history of non-compliance or inability to grant informed consent
ketones in heart failure - effects on cardiac efficiency

Conditions: Heart Failure, Systolic; Ketonemia

Summary: ketones may have beneficial effects on myocardial metabolism and hemodynamics. in the present study, healthy test subjects and patients with heart failure with reduced ejections fraction will be investigated in a randomized cross-over design with ketone infusions and placebo. myocardial efficiency and hemodynamics will be evaluated.

the prevalence of patients with heart failure and reduced ejection fraction (hfref) is 1-2%, and the lifetime risk of heart failure at age 55 years is approximately 30%. despite advances in treatment, hospitalization rate and mortality remains high. it is well known that myocardial metabolism changes during development of hfref, and may contribute to contractile dysfunction. however, the myocardium can be considered an omnivore regarding substrate utilization, conferring an important adaptive property. hence, it metabolizes either glucose, lipids, lactate, amino acids or ketones (3-hydroxybutyrate) depending on substrate availability, hormonal status and cardiac demands. these substrates differ with regard to myocardial energy efficiency (mee) (cardiac work related to oxygen consumption). since high mee is associated with a better prognosis in hfref, manipulating substrate uptake could be a new treatment modality in heart failure patients. recently, it was shown that the human myocardium increases 3-hydroxybutyrate (3-ohb) metabolism during development of hfref. these changes may be beneficial as 3-ohb could increase myocardial efficiency and lower oxidative stress by scavenging free radicals. however, until now this has not been investigated in clinical trials, and the effect of 3-ohb on cardiac function, oxygen consumption and perfusion remains undetermined in hfref patients. in the present study the investigators will evaluate whether elevated circulating 3-ohb affect myocardial oxygen consumption, mee and perfusion in healthy subjects and patients with hfref, and whether 3-ohb affect hemodynamics and contractile function. 10 healthy test subjects and 20 hfref patients will be subjected to placebo and 3-ohb infusion in a randomized cross-over design. acetate-pet, echocardiography and right sided heart catheterization will be applied.

Eligibility criteria:
inclusion criteria: * for participants with heart failure: * symptoms of heart failure nyha 2-3 * lvef\<40% for all participants: * negative hcg for women in the pregnant age exclusion criteria: * significant cardiac valve disease * signs or history of major myocardial infarction (stemi) within 3 months * other disease or treatment making subject unsuitable for study participation * treatment for diabetes or hba1c level \>7%

Keywords: myocardial metabolism positron emission tomography echocardiography right sided heart catheterization
improving ambulation post stroke with robotic training

Conditions: Stroke

Summary: the purpose of this research study is to look at a new rehabilitation technique for individuals who have suffered a stroke and have difficulties walking. this study is designed to compare robot-assisted (lokomat) rehabilitation therapy with standard physical therapy in order to improve walking post-stroke. this research project will be conducted as a pilot randomized controlled trial that compares the effectiveness of lokomat versus conventional physical therapy in improving the ambulation and gait of chronic stroke patients. the project will provide important pilot data that could indicate whether or not the effectiveness of lokomat training is superior to that of standard physical therapy and if a definitive and larger clinical trial is warranted.


Eligibility criteria:
inclusion criteria: * subjects with ischemic or hemorrhagic stroke confirmed by cerebral computed tomography (ct) or magnetic resonance imaging (mri) scan * age\>18 * at least 3 months post stroke at time of enrollment into study * ability to walk at least 10 feet with maximum 1 person assist, but not to walk in the community independently * residual paresis in the lower extremity as defined by the national institute of health stroke scale lower extremity motor score 2-4 * ability to perform lokomat ambulation training with assistance of 1 therapist * ability to follow a three-step command * physician approval for patient participation * ability to give informed consent * completed their rehabilitation services, i.e., receiving no concurrent physical, occupational, or speech therapies exclusion criteria: * serious cardiac condition * uncontrolled blood pressure, defined as \> 200 or diastolic \> 100 at rest * hx of serious chronic obstructive pulmonary disease or oxygen dependence * sever weight bearing pain * lower extremity amputation * claudication while walking * life expectancy \< 1 year * history of deep vein thrombosis/pulmonary embolism (dvt/pe) within 6 months * severe orthopedic problem * any medical or psychiatric condition that the investigators believe would make the patient unable to participate in this study